國立虎尾科技大學 |

Pharmacology and therapeutics of asthma and COPD

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Pharmacology and therapeutics of asthma and COPD/ edited by Clive P. Page, Peter J. Barnes.
remainder title:	Pharmacology and therapeutics of asthma and chronic obstructive pulmonary disease
other author:	Page, Clive P.
Published:	Cham :Springer International Publishing : : 2017.,
Description:	x, 285 p. :ill., digital ; : 24 cm.;
Contained By:	Springer eBooks
Subject:	Asthma - Chemotherapy. -
Online resource:	http://dx.doi.org/10.1007/978-3-319-52175-6
ISBN:	9783319521756

Pharmacology and therapeutics of asthma and COPD
Pharmacology and therapeutics of asthma and COPD[electronic resource] /Pharmacology and therapeutics of asthma and chronic obstructive pulmonary diseaseedited by Clive P. Page, Peter J. Barnes. - Cham :Springer International Publishing :2017. - x, 285 p. :ill., digital ;24 cm. - Handbook of experimental pharmacology,v.2370171-2004 ;. - Handbook of experimental pharmacology ;v.212..

Pathogenesis of bronchial asthma and chronic obstructive pulmonary disease - common diseases with unmet needs -- Beta 2 agonists -- Muscarinic receptor antagonists -- Xanthines and Phosphodiesterase inhibitors -- Glucocorticosteroids -- Fixed dose combination inhalers -- Anti-IgE and biologic approaches for the treatment of asthma -- Leukotriene receptor antagonists and anti-allergy drugs -- Novel anti-inflammatory drugs -- Bifunctional drugs for the treatment of respiratory diseases -- Drugs affecting TRP channels -- Evaluation of new drugs for asthma and COPD: endpoints, biomarkers and clinical trial design -- Drug delivery devices for inhaled medicines.

The present volume is supposed to be a major reference resource for chest physicians and those involved in the development of novel pharmaceutical entities for these diseases. Internationally recognized authorities review the most important new information on the advances in our understanding of the pathogenesis and treatment of these diseases, including the substantial advances in the topical delivery of inhaled medicines. Each chapter is extensively referenced, generously illustrated with clear diagrams and photographs, and represents a state-of-the-art review of this important area of respiratory medicine.

ISBN: 9783319521756

Standard No.: 10.1007/978-3-319-52175-6doiSubjects--Topical Terms:

872261
Asthma
--Chemotherapy.

LC Class. No.: RC591

Dewey Class. No.: 616.238

Pharmacology and therapeutics of asthma and COPD
LDR:02402nam a2200337 a 4500 001 958701
003 DE-He213
005 20170206162855.0
006 m d
007 cr nn 008maaau
008 201118s2017 gw s 0 eng d
020 $a 9783319521756 $q (electronic bk.)
020 $a 9783319521732 $q (paper)
024 7 $a 10.1007/978-3-319-52175-6 $2 doi
035 $a 978-3-319-52175-6
040 $a GP $c GP
041 0 $a eng
050 4 $a RC591
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
082 0 4 $a 616.238 $2 23
090 $a RC591 $b .P536 2017
245 0 0 $a Pharmacology and therapeutics of asthma and COPD $h [electronic resource] / $c edited by Clive P. Page, Peter J. Barnes.
246 3 $a Pharmacology and therapeutics of asthma and chronic obstructive pulmonary disease
260 $a Cham : $c 2017. $b Springer International Publishing : $b Imprint: Springer,
300 $a x, 285 p. : $b ill., digital ; $c 24 cm.
490 1 $a Handbook of experimental pharmacology, $x 0171-2004 ; $v v.237
505 0 $a Pathogenesis of bronchial asthma and chronic obstructive pulmonary disease - common diseases with unmet needs -- Beta 2 agonists -- Muscarinic receptor antagonists -- Xanthines and Phosphodiesterase inhibitors -- Glucocorticosteroids -- Fixed dose combination inhalers -- Anti-IgE and biologic approaches for the treatment of asthma -- Leukotriene receptor antagonists and anti-allergy drugs -- Novel anti-inflammatory drugs -- Bifunctional drugs for the treatment of respiratory diseases -- Drugs affecting TRP channels -- Evaluation of new drugs for asthma and COPD: endpoints, biomarkers and clinical trial design -- Drug delivery devices for inhaled medicines.
520 $a The present volume is supposed to be a major reference resource for chest physicians and those involved in the development of novel pharmaceutical entities for these diseases. Internationally recognized authorities review the most important new information on the advances in our understanding of the pathogenesis and treatment of these diseases, including the substantial advances in the topical delivery of inhaled medicines. Each chapter is extensively referenced, generously illustrated with clear diagrams and photographs, and represents a state-of-the-art review of this important area of respiratory medicine.
650 0 $a Asthma $x Chemotherapy. $3 872261
650 0 $a Lungs $x Diseases, Obstructive $x Chemotherapy. $3 581962
650 0 $a Antiasthmatic agents. $3 872262
650 1 4 $a Biomedicine. $3 593880
650 2 4 $a Pharmacology/Toxicology. $3 593882
650 2 4 $a Pneumology/Respiratory System. $3 668561
650 2 4 $a Dermatology. $3 669082
700 1 $a Page, Clive P. $3 885218
700 1 $a Barnes, Peter J. $3 1251048
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
830 0 $a Handbook of experimental pharmacology ; $v v.212. $3 882814
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-52175-6
950 $a Biomedical and Life Sciences (Springer-11642)